Navigation Links
Global collaboration forms to advance Japanese TB vaccine technology

January 27, 2014 Osaka, Japan and Rockville, MD, USA - Japan's National Institute of Biomedical Innovation ("NIBIO"), Aeras and Create Vaccine Company, Ltd ("CREATE") announce today that they signed a collaboration agreement on December 26, 2013, on the preclinical and clinical development of new mucosal tuberculosis (TB) vaccines based on NIBIO's human parainfluenza type-2 (rhPIV2) vector technology.

"These will be important candidates; designed to target mucous membranes to keep TB from entering the lungs," said Tom Evans, MD, President and CEO of Aeras, a nonprofit biotech advancing TB vaccines globally. "This type of collaboration among global experts is exactly the approach needed to find an effective vaccine that will end tuberculosis in Japan and around the world."

The collaboration is supported through a generous grant from the Global Health Innovative Technology Fund (GHIT), a new partnership formed to facilitate international partnerships that enable Japanese technology, innovations, and insights to play a more direct role in reducing disparities in health between the rich and the poor of the world.

The vaccine platform was created by Tsukuba Primate Research Center at NIBIO. "Based on the promising results of early research and the improved safety profile of candidates using this rhPIV2 platform, we believe that this platform has great possibility," said Dr. Yasuhiro Yasutomi (Director of Tsukuba Primate Research Center, NIBIO). "Further studies contribute to the ultimate goal of establishing a new vaccine strategy that can definitely prevent TB."

CREATE is a joint venture company created by Dainippon Sumitomo Pharma and Japan BCG Laboratory to develop and market TB vaccines developed in partnership with NIBIO and Aeras.

The collaboration announced today will advance vaccine candidates based on the rhPIV2 technology through preclinical stages with a goal to advance to safety and immunogenicity testing in clinical trials. The partners will collaborate jointly to establish development criteria and assess progress through agreed upon development milestones. This will include the characterization of new vaccine constructs with a variety of antigens, the conduct of immunology studies to identify the most promising novel vaccines and the establishment of current good manufacturing practices (cGMP).

"Development of TB vaccines is a new challenge." said Koichi Kozuki, President of CREATE. "The exciting partnership among NIBIO, Aeras and CREATE will accelerate development efforts for clinical application of new TB vaccines to the patients who need it."

TB is one of the deadliest and most disabling diseases in the world today. Each year, more than 8.6 million people become sick with TB and 1.3 million people die of the disease. Although its burden is spread across all age groups, it exacts its greatest toll on individuals during their most productive years, from ages 15 to 44. The global emergence and spread of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), now found in all countries surveyed worldwide, are confounding efforts to halt the spread of TB and are imposing enormous personal costs and a significant economic burden on national health systems. The cost of treating MDR-TB can be 200 times greater than for drug-susceptible TB. In Japan every year, more than 20,000 people contract TB and more than 2,000 die from the disease.

Contact: Annmarie Leadman

Related medicine news :

1. Global Biometrics Market In The Healthcare Industry 2014-2018: Worldwide Industry Share, Investment Trends, Growth, Size, Strategy And Forecast Research Report
2. Global In Vitro Diagnostics (IVD) Market 2013
3. Industry Analysis, Size, Share, Growth, Trends and Forecast Research Report Available Online by
4. Global Sealant Industry & China Aerogel Market Size Analysis in New Research Reports at
5. Global Fermentation Chemicals Market Research Report: Transparency Market Research
6. Commercial Airport Lighting Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
7. Global Medical Publishing Market 2014-2018: Worldwide Industry Share, Investment Trends, Growth, Size, Strategy and Forecast Research Report
8. Global Ostomy Care Industry Trend & 2017 Opportunities Analyzed in New Research Study at
9. China Digital Radiography Industry & Global CBCT Market Analysis in a New Research Study Available at
10. CeBIT Global Conference March 2014 in Hannover Germany Features Discount Pricing from Absolute Exhibits
11. 2014 Vitamin C and Vitamin A Market China Global Analysis in a New Research Available at
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic foot wounds are ... are well aware that psychology-based patient non-compliance (disobedience of a health care provider’s ... diseases of the diabetic foot. The American Board of Multiple Specialties in ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... radiographic technicians must mark the film for accurate interpretation by the radiologist. The ... Fortunately, an inventor from Sacramento, Calif., has found a way to alleviate this ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), ... at the Radiological Society of North America (RSNA) 2015 annual meeting through December ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next ... selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an ... was recognized as a finalist in the category of Digital Solutions for its ...
(Date:12/1/2015)... ... ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, announced ... the United States. Clarity is a Superior Dual Wavelength Platform which combines two ... platform that is easy to own and operate. , For over a decade, ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel ... the company will present at the LD Micro Main Event. ... Sunset Boulevard Hotel in Los Angeles, CA. ... present on Thursday, December 3, at 9:00 am Pacific time ... at least 10 minutes prior to the start of the ...
(Date:12/1/2015)... Dec. 1, 2015   MabVax Therapeutics Holdings, Inc ... announces it has filed an Investigational New Drug Application ... for the Company,s lead fully human antibody product HuMab ... MabVax plans to initiate the Phase I clinical trial ... --> The planned Phase I trial will ...
(Date:12/1/2015)... 2015   Craneware, Inc ., the healthcare ... announced the company will showcase a new version ... solution at the American Society for Health-System ... The new features are focused on simplifying and ... managing enterprise-wide pharmacy charges to ensure compliance and ...
Breaking Medicine Technology: